The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.


Approval Status:

Approved January 1998

Specific Treatments:

Hormone replacement therapy

General Information

Prempro has been cleared for marketing with a new, increased progestin dose. The new dose of Prempro (conjugated estrogens/medroxyprogesterone acetate tablets) contains 0.625 mg Premarin (conjugated estrogens) and 5 mg medroxyprogesterone acetate. The previously approved dose contains 0.625 mg Premarin and 2.5 mg medroxyprogesterone acetate. The drug is approved for use as a combination estrogen and progestin hormone replacement therapy.

Side Effects

Common side effects may include nausea, breast tenderness, headaches, and abdominal pain.